Braving New Frontiers in Cancer Monitoring - Learn Look Locate (LLL) Hosts Educational Natera™ Site for Personalized Signatera™ Tests

TUCSON, Ariz., Dec. 11, 2023 /PRNewswire/ -- Following a previous collaboration with Natera, a global cell-free DNA testing leader, LLL announced that it would host a dedicated webpage,  for Natera's revolutionary molecular residual disease assay (MRD) test: Signatera. MRD is used to describe the small amount of residual cancer cells that patients retain after cancer treatment and is used as a major predictor of relapse. The new LLL page will highlight the benefits of Signatera, while also giving patients and readers access to LLL's vast archive of breast cancer resources.